During the review, the committee will likely consider: The extensive body of published research on GHK-Cu (decades of studies) Safety data for both injectable and topical routes The clinical rationale for copper peptide therapy in anti-aging and wound healing Quality control considerations for compounding GHK-Cu formulations Public comments from patients, dermatologists, anti-aging practitioners, and pharmacies Given GHK-Cu's long history of use and substantial research base, many in the peptide therapy community are cautiously optimistic about a positive PCAC recommendation particularly for the topical route
Any discussion of published studies summarises the scientific literature relating to the individual peptide components rather than the intended use of the combined formulation
How it works: Supports cellular repair and scalp immunity
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
The direction of modulation is notable: many genes associated with DNA repair, antioxidant response, and tissue remodeling are upregulated, while genes linked to inflammation and tumor progression are downregulated
Novartis supported the expansion application with topline data from the Phase III NATALEE trial, in which treatment with Kisqali led to a significant improvement in disease-free survival versus standard adjuvant endocrine therapy alone, according to the company
